Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine

Cassione et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case -50% Improvement Relative Risk HCQ for COVID-19  Cassione et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 165 patients in Italy More cases with HCQ (not stat. sig., p=0.59) c19hcq.org Cassione et al., Annals of the Rheumat.., May 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 and 4 confirmed cases. No mortality, one ICU case. 7 patients had no symptoms despite contact with a COVID-19 patient.
No adjustment for concomitant medications or severity of SLE. Confounding by indication.
This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.
risk of case, 49.6% higher, RR 1.50, p = 0.59, treatment 10 of 127 (7.9%), control 2 of 38 (5.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cassione et al., 12 May 2020, retrospective, Italy, peer-reviewed, survey, median age 52.5, 6 authors.
This PaperHCQAll
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Professor Carlomaurizio Montecucco, Lorenzo Cavagna
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717
Handling editor Josef S Smolen Acknowledgements The authors wish to thank Dr Luciano Perotti from the ICU department of our Hospital for his invaluable contribution to the good outcome of the admitted SLE patient.
References
Ferner, Aronson, Chloroquine and hydroxychloroquine in covid-19, BMJ, doi:10.1136/bmj.m1432
Hollander, Carr, Virtually perfect? telemedicine for Covid-19, N Engl J Med, doi:10.1056/NEJMp2003539
Joob, Wiwanitkit, Sle, hydroxychloroquine and NO SLE patients with COVID-19: a comment, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217506
Mathian, Mahevas, Rohmer, Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217566
Monti, Balduzzi, Delvino, Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217424
Remuzzi, Remuzzi, COVID-19 and Italy: what next?, Lancet, doi:10.1016/S0140-6736(20)30627-9
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T07:53:04Z', 'timestamp': 1712562784455}, 'reference-count': 7, 'publisher': 'BMJ', 'issue': '10', 'license': [ { 'start': { 'date-parts': [[2020, 5, 12]], 'date-time': '2020-05-12T00:00:00Z', 'timestamp': 1589241600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://bmj.com/coronavirus/usage'}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 10]]}, 'DOI': '10.1136/annrheumdis-2020-217717', 'type': 'journal-article', 'created': {'date-parts': [[2020, 5, 23]], 'date-time': '2020-05-23T21:15:14Z', 'timestamp': 1590268514000}, 'page': '1382-1383', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 77, 'title': 'COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by ' 'telemedicine', 'prefix': '10.1136', 'volume': '79', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6578-6938', 'authenticated-orcid': False, 'given': 'Emanuele', 'family': 'Bozzalla Cassione', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5042-1282', 'authenticated-orcid': False, 'given': 'Giovanni', 'family': 'Zanframundo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alessandro', 'family': 'Biglia', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2557-8514', 'authenticated-orcid': False, 'given': 'Veronica', 'family': 'Codullo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlomaurizio', 'family': 'Montecucco', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lorenzo', 'family': 'Cavagna', 'sequence': 'additional', 'affiliation': []}], 'member': '239', 'published-online': {'date-parts': [[2020, 5, 12]]}, 'reference': [ { 'key': '2021051223100650000_79.10.1382.1', 'doi-asserted-by': 'crossref', 'first-page': '1225', 'DOI': '10.1016/S0140-6736(20)30627-9', 'article-title': 'COVID-19 and Italy: what next?', 'volume': '395', 'author': 'Remuzzi', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '2021051223100650000_79.10.1382.2', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217424'}, { 'key': '2021051223100650000_79.10.1382.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217506'}, { 'key': '2021051223100650000_79.10.1382.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/annrheumdis-2020-217566'}, { 'key': '2021051223100650000_79.10.1382.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMp2003539'}, { 'key': '2021051223100650000_79.10.1382.6', 'unstructured': 'Epidemia COVID-19. Available: ' 'https://www.epicentro.iss.it/coronavirus/bollettino/Bolletino-sorveglianza-integrata-COVID-19_23-aprile-2020_appendix.pdf'}, { 'key': '2021051223100650000_79.10.1382.7', 'doi-asserted-by': 'crossref', 'unstructured': 'Ferner RE , Aronson JK . Chloroquine and hydroxychloroquine in covid-19. ' 'BMJ;1:m1432.doi:10.1136/bmj.m1432', 'DOI': '10.1136/bmj.m1432'}], 'container-title': 'Annals of the Rheumatic Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-217717', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 5, 13]], 'date-time': '2021-05-13T06:11:30Z', 'timestamp': 1620886290000}, 'score': 1, 'resource': {'primary': {'URL': 'https://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2020-217717'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 12]]}, 'references-count': 7, 'journal-issue': { 'issue': '10', 'published-online': {'date-parts': [[2020, 9, 14]]}, 'published-print': {'date-parts': [[2020, 10]]}}, 'alternative-id': ['10.1136/annrheumdis-2020-217717'], 'URL': 'http://dx.doi.org/10.1136/annrheumdis-2020-217717', 'relation': {}, 'ISSN': ['0003-4967', '1468-2060'], 'subject': [ 'General Biochemistry, Genetics and Molecular Biology', 'Immunology', 'Immunology and Allergy', 'Rheumatology'], 'container-title-short': 'Ann Rheum Dis', 'published': {'date-parts': [[2020, 5, 12]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit